Caisse de depot et placement du Quebec Has $7.55 Million Position in Pfizer Inc. $PFE

Caisse de depot et placement du Quebec lessened its position in Pfizer Inc. (NYSE:PFE - Free Report) by 90.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 313,644 shares of the biopharmaceutical company's stock after selling 2,948,297 shares during the period. Caisse de depot et placement du Quebec's holdings in Pfizer were worth $7,553,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Evolution Wealth Management Inc. raised its stake in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 566 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the fourth quarter valued at about $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer in the second quarter worth about $26,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 427 shares during the period. Finally, Global Trust Asset Management LLC raised its position in shares of Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock worth $33,000 after purchasing an additional 650 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on PFE shares. Cantor Fitzgerald reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Weiss Ratings downgraded shares of Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 17th. UBS Group reaffirmed a "neutral" rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. JPMorgan Chase & Co. reduced their price target on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a report on Wednesday, July 8th. Finally, BMO Capital Markets cut their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus target price of $28.28.

Pfizer Stock Down 0.2%

Pfizer stock opened at $27.95 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a fifty day simple moving average of $25.55 and a 200 day simple moving average of $26.30. The company has a market cap of $159.31 billion, a P/E ratio of 36.78 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer's dividend payout ratio is 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source